핵심 개념
The iLFT platform can enhance the diagnosis and management of chronic liver disease in primary care settings by automating further testing and providing recommendations based on liver function test results.
초록
The study presented real-world data on the use of the iLFT platform in NHS Tayside, Scotland, over a 5-year period from 2018 to 2023. The iLFT platform is an automated algorithm that analyzes standard liver function test results and initiates further fibrosis scoring and etiologic testing to determine the cause of liver dysfunction.
Key highlights:
- Of the 26,459 iLFT tests performed, 68.3% required further testing beyond the initial liver function test.
- Further testing generated 20,895 outcomes, with isolated abnormal alanine transaminase (ALT) without fibrosis being the most frequent (23.7%), likely due to metabolic dysfunction-associated steatotic liver disease (MASLD).
- Overall, half of the cascaded samples had a positive etiologic diagnosis, with alcoholic liver disease (ALD) and MASLD being the most common.
- 20% of cascaded tests identified potentially significant liver fibrosis.
- 69.9% of outcomes recommended that patients could be safely managed in primary care, and the inclusion of automatic Enhanced Liver Fibrosis (ELF) testing in 2020 further reduced the requirement for referral to secondary care by 34%.
- The iLFT platform ensures that the right patients receive appropriate follow-on testing and recommendations for referral to secondary care, helping primary care practitioners identify the cause of chronic liver disease.
통계
Of the 26,459 iLFT tests performed between 2018 and 2023, 68.3% (18,079) required further testing beyond the initial liver function test, whereas 31.7% (8,380) did not.
Further testing generated 20,895 outcomes, of which, isolated abnormal alanine transaminase (ALT) without fibrosis was most frequent (23.7%).
20% of cascaded tests identified potentially significant liver fibrosis.
69.9% of outcomes recommended that patients could be safely managed in primary care, and the inclusion of automatic Enhanced Liver Fibrosis (ELF) testing in 2020 further reduced the requirement for referral to secondary care by 34%.
인용구
"Without this algorithm, the 18,000 patients who had algorithm-directed further testing would have had to go back to the [primary care practitioner] to obtain the additional tests, and the [primary care practitioner] would need to interpret them too."
"iLFTs ensure the right patients get automated, appropriate follow-on testing and subsequent recommendation of referral to secondary care if necessary, and importantly iLFT helps the primary care practitioner identify the cause of chronic liver disease."